Three top officers resign at Zhongchao Inc. (ZCMD) amid business strategy change

Rhea-AI Filing Summary

Zhongchao Inc. filed a Form 6-K to report that three senior officers resigned on March 15, 2026 following an adjustment of the company’s business strategies. Xuejun Chen stepped down as Chief Medical Officer, Baoqian Tian resigned as Chief Sales Officer, and Shuang Wu left the role of Chief Operating Officer.

The resignations were effective immediately and the company states they were not due to any disagreement regarding operations, policies, or practices. The report is also incorporated by reference into Zhongchao’s existing Form S-8 and Form F-3 registration statements.

Positive

• None.

Negative

• Simultaneous loss of three senior officers — The immediate resignations of the Chief Medical Officer, Chief Sales Officer, and Chief Operating Officer following a strategy shift may create leadership gaps across key medical, commercial, and operational functions.

Insights

Corporate governance analyst

Three C-level officers resign simultaneously amid strategy shift, raising potential governance and execution concerns.

Zhongchao Inc. discloses that its Chief Medical Officer, Chief Sales Officer, and Chief Operating Officer all resigned effective immediately on March 15, 2026. The company attributes these departures to an adjustment of business strategies, while stating there were no disagreements over operations, policies, or practices.

Simultaneous exits of multiple senior executives can disrupt continuity in medical, commercial, and operational leadership. The filing does not outline succession plans or replacements, leaving questions about short-term execution capacity and how responsibilities will be redistributed within the leadership team.

The report is also incorporated by reference into existing Form S-8 and Form F-3 registration statements, which keeps these leadership changes formally connected to outstanding equity compensation and potential securities offerings. Subsequent filings may clarify new appointments or governance changes as the updated business strategy is implemented.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Zhongchao Inc.

(Exact name of registrant as specified in its charter)

Room 2504, OOCL Plaza

841 Yan’an Middle Road

Jing’An District, Shanghai, China 200040

Tel: 021-32205987

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒      Form 40-F  ☐

Departure of Officers

On March 15, 2026, three officers of Zhongchao Inc. (the “Company”) resigned from their positions as officers of the Company as a result of the Company’s adjustment of business strategies. Xuejun Chen resigned from his position as the Chief Medical Officer, Mr. Baoqian Tian resigned from his position as the Chief Sales Officer, and Shuang Wu resigned from her position as the Chief Operating Officer, effective immediately. Their resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

INCORPORATION BY REFERENCE

This Report on Form 6-K is hereby incorporated by reference in the Company’s registration statement on Form S-8 (File No. 333-289791), Form S-8 (File No. 333-288589), Form F-3 (File No. 333-279667) and Form F-3 (File No. 333-283916) to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Zhongchao Inc.
Date: March 20, 2026	By:	/s/ Weiguang Yang
		Weiguang Yang
		Chief Executive Officer

2

FAQ

What leadership changes did Zhongchao Inc. (ZCMD) report in the March 2026 Form 6-K?

Zhongchao Inc. reported that three senior officers resigned effective March 15, 2026. The Chief Medical Officer, Chief Sales Officer, and Chief Operating Officer all stepped down as part of an adjustment to the company’s business strategies.

Why did three officers resign from Zhongchao Inc. (ZCMD) on March 15, 2026?

The three officers resigned as a result of Zhongchao Inc.’s adjustment of business strategies. The company explicitly states their resignations were not due to any disagreement regarding its operations, policies, or practices, suggesting the moves are tied to strategic realignment.

Were the Zhongchao Inc. (ZCMD) officer resignations related to disagreements with the company?

No. Zhongchao Inc. states the resignations of its Chief Medical Officer, Chief Sales Officer, and Chief Operating Officer were not due to any disagreement. The filing specifies there were no disputes concerning the company’s operations, policies, or practices.

When were the Zhongchao Inc. (ZCMD) officer resignations effective?

The resignations of Zhongchao Inc.’s Chief Medical Officer, Chief Sales Officer, and Chief Operating Officer were effective immediately on March 15, 2026. This means the leadership changes took effect at once, without a transition period disclosed in the report.

How does this Zhongchao Inc. (ZCMD) Form 6-K interact with existing registration statements?

The report is incorporated by reference into Zhongchao Inc.’s Form S-8 and Form F-3 registration statements. This links the disclosed leadership changes to those existing securities registration documents unless later documents or reports supersede this information.

Which executive signed the March 2026 Zhongchao Inc. (ZCMD) Form 6-K?

Chief Executive Officer Weiguang Yang signed the March 2026 Form 6-K on behalf of Zhongchao Inc. His signature confirms the company’s authorization of the report describing the three officer resignations and their connection to strategy adjustments.